drs. M. Beijert

No picture available
E-mail:
m.beijert umcg.nl

Research

Publications
  1. Radiotherapie bij de oncologische patient: Hematologische ziektebeelden

    Niezink, A., Beijert, M. & Klinker, P., Mar-2021, Radiotherapie bij de oncologische patient. Vol. 5. p. 193-208 15 p.

    Research output: Chapter in Book/Report/Conference proceedingChapterProfessional

  2. Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study

    van der Meulen, M., Bakunina, K., Nijland, M., Minnema, M. C., Cull, G., Stevens, W. B. C., Baars, J. W., Mason, K. D., Beeker, A., Beijert, M., Taphoorn, M. J. B., van den Bent, M. J., Issa, S., Doorduijn, J. K., Bromberg, J. E. C. & Dirven, L., 1-Aug-2020, In : Annals of Oncology. 31, 8, p. 1046-1055 10 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer

    Rigter, L. S., Schaapveld, M., Janus, C. P. M., Krol, A. D. G., van der Maazen, R. W. M., Roesink, J., Zijlstra, J. M., van Imhoff, G. W., Poortmans, P. M. P., Beijert, M., Lugtenburg, P. J., Visser, O., Snaebjornsson, P., van Eggermond, A. M., Aleman, B. M. P., van Leeuwen, F. E. & van Leerdam, M. E., Jan-2019, In : Cancer medicine. 8, 1, p. 190-199 10 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

    Bromberg, J. E. C., Issa, S., Bakunina, K., Minnema, M. C., Seute, T., Durian, M., Cull, G., Schouten, H. C., Stevens, W. B. C., Zijlstra, J. M., Baars, J. W., Nijland, M., Mason, K. D., Beeker, A., van den Bent, M., Beijert, M., Gonzales, M., de Jong, D. & Doorduijn, J. K., Feb-2019, In : Lancet Oncology. 20, 2, p. 216-228 13 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial

    Thomas, J., Ferme, C., Noordijk, E. M., Morschhauser, F., Girinsky, T., Gaillard, I., Lugtenburg, P. J., Andre, M., Lybeert, M. L. M., Stamatoullas, A., Beijert, M., Helias, P., Eghbali, H., Gabarre, J., van der Maazen, R. W. M., Jaubert, J., Bouabdallah, K., Boulat, O., Roesink, J. M., Christian, B., Ong, F., Bordessoule, D., Tertian, G., Gonzalez, H., Vranovsky, A., Quittet, P., Tirelli, U., de Jong, D., Audouin, J., Aleman, B. M. P., Henry-Amar, M., European Org Res Treatment Canc & Grp Etude Lymphomes Adulte, 1-Apr-2018, In : International Journal of Radiation Oncology Biology Physics. 100, 5, p. 1133-1145 13 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (13) »

ID: 440371